ArticleBMC cancer2026
The prognostic value analysis of PIV, PLR, LMR, NPR, and NLR in hilar cholangiocarcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Anatomical Localization on Systemic Inflammatory Markers and Immune Checkpoint CD47 in Desmoid Tumors.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHilar cholangiocarcinoma (HCCA) has a high propensity for early recurrence. We evaluated the prognostic value of preoperative inflammatory biomarkers, Pan‑Immunological Value (PIV), Platelet‑Lymphocyte Ratio (PLR), Lymphocyte‑Monocyte Ratio (LMR), Neutrophil‑Platelet Ratio (NPR), and Neutrophil‑Lymphocyte Ratio (NLR), in resected HCCA.
methodsA retrospective cohort study included 373 HCCA patients undergoing radical resection from January 2017 to May 2022. Patients treated between January 2017 and December 2020 were assigned to the training set (n = 236) for model development. Those treated between January 2021 and May 2022 were assigned to the independent temporal validation set (n = 137), this split approximates a 6:4 ratio. Baseline characteristics were comparable between sets (all P > 0.05). Patients were categorized based on one-year recurrence-free survival (RFS) into early and non-early recurrence groups. Clinical, pathological, and preoperative inflammatory marker data were collected. Statistical analyses included univariate and multivariate Cox proportional hazards regression, Kaplan-Meier curves, and receiver operating characteristic (ROC) curve analysis to assess the prognostic value of the inflammatory markers.
resultsIn univariate analysis, higher PIV, PLR, NLR, NPR and lower LMR were associated with early recurrence (all P < 0.05). To avoid statistical collinearity, separate multivariable Cox models were constructed, each adjusting for clinicopathological factors but including only one inflammatory marker. In these models, PLR (HR = 1.026, P = 0.026), NLR (HR = 1.523, P = 0.011), NPR (HR = 1.831, P = 0.010), and LMR (HR = 0.483, P = 0.001) remained independent predictors of early recurrence; PIV did not (HR = 1.001, P = 0.425). Kaplan‑Meier curves confirmed shorter RFS for patients with high PIV, PLR, NLR, NPR or low LMR (all log‑rank P < 0.001). The combined model integrating all five markers achieved AUCs of 0.857 (training) and 0.908 (validation), outperforming individual markers (AUCs 0.616–0.637).
conclusionThe combined predictive model integrating inflammatory markers PIV, PLR, NLR, NPR, and LMR shows improved prognostic accuracy in HCCA, potentially providing clinically actionable stratification alongside traditional clinical parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.